Accelerating Access to Critical Therapies for Als Reauthorization Act of 2026

Floor Speech

Mr. Speaker, about 5,000 Americans are diagnosed with ALS every year. It is a disease that causes the nervous system to stop working and die, leading to muscle weakness and eventually paralysis. Essentially, when someone gets the diagnosis, it is a death sentence.

I am all too familiar with this disease and its rapid progression because in 1996, I lost my father-in-law to ALS.

The original Accelerating Access to Critical Therapies for ALS Act passed in 2021 and unleashed incredible Federal resources to improve our understanding of this relentless disease in search of a cure. It revolutionized the way FDA uses real-world evidence to foster the development of ALS therapeutics and gave patients a chance to try investigational drugs for rare neurodegenerative diseases.

We have the opportunity today to ensure ALS patients can continue to access promising new therapies, and our preeminent biomedical research institutions can continue to work towards a cure. This reauthorization will provide the continuing statutory basis for the great work that the Accelerating Access to Critical Therapies for ALS Act began, and it couldn't come at a better moment.

We have seen immense research progress in the 5 years since passage. Health Subcommittee members here today heard from Brian Wallach and Sandra Abrevaya in our hearing on this bill a few months ago when they told us with no uncertainty how important it is for people facing down this cruel disease that we keep this momentum going.

Brian and Sandra are an inspiration to all of us and to people everywhere who are seeking cures for these terrible diseases.

I want to tell Congressman Mike Quigley that his unwavering leadership on the original Accelerating Access to Critical Therapies for ALS Act and this reauthorization is saving and improving lives. I thank them for putting us on the path of finding a cure for ALS.

BREAK IN TRANSCRIPT

Source